Navigation Links
Scorpio TS Single Axis Revision Knee System

ProductsScorpio TS Single Axis Revision Knee System
Company Stryker Corporation
Item Scorpio TS Single Axis Revision Knee System
Features 
Description Scorpio TS is designed to maintain a constant center of rotation throughout the range of motion. This provides uniform ligament tension during the transition from full extension to deep flexion. By preserving ligament isometry, Scorpio TS eliminates mid-flexion instability, which is a common concern in revision knee surgery.
Info Stryker Corporation
Customer Service: (269) 385-2600

Related medicine products :

1. Scorpio CR Knee, cruciate retaining single axis
2. Scorpio Posteriorly Stabilized Single Axis Knee
3. Single Skin Hook
4. Single Tantalum Clip (50 Style)
5. Single Beam
6. Single Plate Molteno Implant (S1)
7. Pressure Ridge Single Plate Molteno Implant (D1)
8. Cottle Single Hook
9. Goldman Single Hook
10. Joseph Single Hook
11. Kleinert-Kutz Single Skin Hook
Inquire
... autoimmune testing feature single-well ANA screen... tests including dsDNA, and 6 individual ENA kits:.... In addition, our autoimmune ELISA family include...gG, IgM), Thyroglobulin, Thyroid Microsomal, MPO, ...
... autoimmune testing feature single-well ANA screen... tests including dsDNA, and 6 individual ENA kits:.... In addition, our autoimmune ELISA family include...gG, IgM), Thyroglobulin, Thyroid Microsomal, MPO, ...
... autoimmune testing feature single-well ANA screen... tests including dsDNA, and 6 individual ENA kits:.... In addition, our autoimmune ELISA family include...gG, IgM), Thyroglobulin, Thyroid Microsomal, MPO, ...
Medicine Products:
(Date:10/6/2008)...t. 6 /PRNewswire/ -- Developed in collaboration wi...ades, CA is introducing,Revolutionary Breast Surfa...c Surgery office of Dr. Steve Laverson this week i...he first of its kind, and is based on,breakthrough...with,innovative proprietary software. The XS-300(T...
(Date:10/6/2008)...ct. 6 /PRNewswire/ -- The organizers of Informex a...e on Global Sourcing for the,Pharmaceutical Indust...inceton Marriott in New Jersey USA., The conferen... the,Global Sourcing Council, and boasts an unpara...e likes of Johnson & Johnson, Bristol Myers Squibb...
(Date:10/6/2008)... LegalView recently posted detailed inform...he potentially serious side effects caused by the ... the drug,s potential side effects are the develop... for young adult and child patients. , ...- LegalView, the number one resource for everythin...
(Date:10/6/2008)... Hospital Ship Serving in West Africa Rece...Garden Valley, Texas October 6, 2008 -- www.seamob...l provider of communications services to remote lo...s to the FoxNews channel via satellite to Mercy Sh...ica Mercy. The Africa Mercy is the world,s larges...
Breaking Medicine News(10 mins):Health News:Plan Your Breasts in 3-D 2Health News:Global Sourcing Strategies for the Pharmaceutical Industry 10th - 11th November, Marriott Princeton, New Jersey USA 2Health News:LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis 2Health News:LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis 3Health News:Seamobile Provides Foxnews To Mercy Ships 2Health News:Seamobile Provides Foxnews To Mercy Ships 3
...e Kossoudji has endeavored each day to manage the ...r types of physical strife caused by rheumatoid ar...s many ways as you could possibly imagine, and pre...i. It is a disease that can be manipulated with me...
...n who are on estrogen therapy before the age of 6...of reduction in the risk of Alzheimers disease or ...y form of estrogen hormone therapy before the age ...50%, as compared to women who were not on hormone ...
...or survival for children and young adults with acu...er Hospital at The University of Texas M. D. Ande...eukemia patients over the past decade has shown th... a measure of normal immune cells found on every c...
... for countries that recently have made progress in...eleased on Monday by Save the Children, the New Y...e World's Mothers: Saving the Lives of Children Un...mother and child in 60 developing countries where ...
Other Medicine News:Health News:Aging Gracefully, With a Chronic Disease 2Health News:Lymphocyte Count Found to Be a Predictor of Survival for Young Patients With Leukemia 2Health News:Family Planning Initiatives Central To Reducing Child Mortality in Developing Countries 2
(Date:10/6/2008)...vere patients achieved endoscopic,response and mor... Week 10,in data from a 54-week open-label study p...gy (ACG) Annual Scientific Meeting, ORLANDO, Fla....from a,large, prospective study investigating endo...biologic compound. The data presented at the Ameri...
(Date:10/6/2008)...ny,s Bioabsorbable Stent - Also,Slated for Present.../ -- Data from multiple clinical trials of,the wor...Bio-engineered R,stent, will be presented next wee... symposium, TCT 2008, in Washington, D.C., Robber...Center in,Amsterdam will provide a Genous clinical...
(Date:10/3/2008)...-FirstCall/ -- deCODE genetics,(Nasdaq: DCGN ) to... drug,(IND) application for DG071, the company,s n... 4 (PDE4), with the US Food and Drug Administratio...and potentially safer means,of targeting PDE4 to c...d,with Alzheimer,s disease and other disorders in ...
(Date:10/2/2008)...aleads has obtained from the,French Medicine Agenc...ascending dose Phase I study with PL37, its lead c...Neuropathic pain is a major chronic pain condition...lation of up to 6%, according to the most,recent s... diabetes,antiviral or antitumor chemotherapy sur...
Breaking Medicine Technology:CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 2CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 3CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 4CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 5CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 6CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 7Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008 2Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008 3deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 2deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 3deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 4deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 5Pharmaleads' Lead Candidate for Pain, PL37, Enters Phase I 2Campbell Alliance Sales Practice to Present Workshop at SPBT Annual Conference 5476 1Campbell Alliance Sales Practice to Present Workshop at SPBT Annual Conference 5476 2Campbell Alliance Sales Practice to Present Workshop at SPBT Annual Conference 5476 3Adding epratuzumab to standard therapy 19583 1Adding epratuzumab to standard therapy 19583 2Top Academic Medical Centers Research Institutions and Partners Gather Share Experiences and Success Stories at Velos eResearch Annual Meeting 2102 1Top Academic Medical Centers Research Institutions and Partners Gather Share Experiences and Success Stories at Velos eResearch Annual Meeting 2102 2Top Academic Medical Centers Research Institutions and Partners Gather Share Experiences and Success Stories at Velos eResearch Annual Meeting 2102 3Shengtai Pharmaceutical Inc Reports Third Quarter Results of Fiscal Year 2008 19578 1Shengtai Pharmaceutical Inc Reports Third Quarter Results of Fiscal Year 2008 19578 2Shengtai Pharmaceutical Inc Reports Third Quarter Results of Fiscal Year 2008 19578 3Shengtai Pharmaceutical Inc Reports Third Quarter Results of Fiscal Year 2008 19578 4Shengtai Pharmaceutical Inc Reports Third Quarter Results of Fiscal Year 2008 19578 5Shengtai Pharmaceutical Inc Reports Third Quarter Results of Fiscal Year 2008 19578 6Shengtai Pharmaceutical Inc Reports Third Quarter Results of Fiscal Year 2008 19578 7Shengtai Pharmaceutical Inc Reports Third Quarter Results of Fiscal Year 2008 19578 8Shengtai Pharmaceutical Inc Reports Third Quarter Results of Fiscal Year 2008 19578 9Shengtai Pharmaceutical Inc Reports Third Quarter Results of Fiscal Year 2008 19578 10Shengtai Pharmaceutical Inc Reports Third Quarter Results of Fiscal Year 2008 19578 11Shengtai Pharmaceutical Inc Reports Third Quarter Results of Fiscal Year 2008 19578 12
...bodies Inhibited Tumor Growth By, ...grine,s Antibodies that Selectively Inhibit VEGF R... Non-Selective Approaches - , - These Results Alon...pport , Advancing Peregrine,s Anti-VEGF Program to...Calif., April 16, 2007,/PRNewswire-FirstCall/ -- P...
...swire-FirstCall/ --,Threshold Pharmaceuticals, Inc...ng its oncology pipeline, which includes two,precl...Prodrug,TH-302, and two research presentations fr...entations will take place at the 2007,American Ass...,being held April 14 - 18, 2007, at the Los Angele...
Other Medicine Technology:Data Presented at AACR Meeting Shows Peregrine's Selective,Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical,Cancer Models 2Data Presented at AACR Meeting Shows Peregrine's Selective,Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical,Cancer Models 3Data Presented at AACR Meeting Shows Peregrine's Selective,Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical,Cancer Models 4Data Presented at AACR Meeting Shows Peregrine's Selective,Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical,Cancer Models 5Threshold Pharmaceuticals Announces Multiple Presentations on,Oncology Pipeline at the 2007 American Association for Cancer,Research (AACR) Annual Meeting 2Threshold Pharmaceuticals Announces Multiple Presentations on,Oncology Pipeline at the 2007 American Association for Cancer,Research (AACR) Annual Meeting 3